Coronavirus Genetically Redirected to the Epidermal Growth Factor Receptor Exhibits Effective Antitumor Activity against a Malignant Glioblastoma by Verheije, M.H. et al.
  Published Ahead of Print 13 May 2009. 
2009, 83(15):7507. DOI: 10.1128/JVI.00495-09. J. Virol. 
W. van Beusechem and Peter J. M. Rottier
Würdinger, Guy C. M. Grinwis, Winald R. Gerritsen, Victor 
Monique H. Verheije, Martine L. M. Lamfers, Thomas
 
Malignant Glioblastoma
Effective Antitumor Activity against a 
ExhibitsEpidermal Growth Factor Receptor 
Coronavirus Genetically Redirected to the
http://jvi.asm.org/content/83/15/7507
Updated information and services can be found at: 
These include:
REFERENCES
http://jvi.asm.org/content/83/15/7507#ref-list-1at: 
This article cites 50 articles, 24 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 O
ctober 25, 2012 by VRIJE UNIVERSITEIT
http://jvi.asm.org/
D
ow
nloaded from
 
JOURNAL OF VIROLOGY, Aug. 2009, p. 7507–7516 Vol. 83, No. 15
0022-538X/09/$08.000 doi:10.1128/JVI.00495-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Coronavirus Genetically Redirected to the Epidermal Growth Factor
Receptor Exhibits Effective Antitumor Activity against a
Malignant Glioblastoma
Monique H. Verheije,1 Martine L. M. Lamfers,2 Thomas Wu¨rdinger,1† Guy C. M. Grinwis,3
Winald R. Gerritsen,4 Victor W. van Beusechem,4 and Peter J. M. Rottier1*
Virology Division, Department of Infectious Diseases and Immunology, Utrecht University, Utrecht, The Netherlands1; Department of
Neurosurgery, Erasmus University, Rotterdam, The Netherlands2; Pathology Division, Department of Pathobiology, Utrecht University,
Utrecht, The Netherlands3; and Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands4
Received 10 March 2009/Accepted 6 May 2009
Coronaviruses are positive-strand RNA viruses with features attractive for oncolytic therapy. To investigate
this potential, we redirected the coronavirus murine hepatitis virus (MHV), which is normally unable to infect
human cells, to human tumor cells by using a soluble receptor (soR)-based expression construct fused to an
epidermal growth factor (EGF) receptor targeting moiety. Addition of this adapter protein to MHV allowed
infection of otherwise nonsusceptible, EGF receptor (EGFR)-expressing cell cultures. We introduced the
sequence encoding the adaptor protein soR-EGF into the MHV genome to generate a self-targeted virus
capable of multiround infection. The resulting recombinant MHV was viable and had indeed acquired the
ability to infect all glioblastoma cell lines tested in vitro. Infection of malignant human glioblastoma
U87EGFR cells gave rise to release of progeny virus and efficient cell killing in vitro. To investigate the
oncolytic capacity of the virus in vivo, we used an orthotopic U87EGFR xenograft mouse model. Treatment
of mice bearing a lethal intracranial U87EGFR tumor by injection with MHVsoR-EGF significantly pro-
longed survival compared to phosphate-buffered saline-treated (P  0.001) and control virus-treated (P 
0.004) animals, and no recurrent tumor load was observed. However, some adverse effects were seen in normal
mouse brain tissues that were likely caused by the natural murine tropism of MHV. This is the first demon-
stration of oncolytic activity of a coronavirus in vivo. It suggests that nonhuman coronaviruses may be
attractive new therapeutic agents against human tumors.
Already for quite some years oncolytic viruses are being
investigated for use in human tumor therapy (for recent re-
views, see references 3, 16, 22, 37, and 44). Their success in
destroying human cancer cells depends on their ability to se-
lectively infect and kill these cells. Although some oncolytic
viruses appear to have a natural tropism for tumor cells, most
viruses need to be modified in some way to achieve infection
and/or lytic activity in these cells. One of the ways to accom-
plish specific infection of tumor cells is by redirecting the virus
to epitopes expressed on such cells. Thus, different targeting
approaches have been explored for a variety of viruses. These
include pseudotyping, modification of viral surface proteins,
and the use of bispecific adapters (14, 35, 45). All of these
approaches require that the viability of the virus is not ham-
pered and that the targeting moiety is properly exposed to
allow directed infection. The ability to genetically modify a
particular virus combined with the availability of an appropri-
ate targeting epitope determines the success of the approaches.
Coronaviruses are enveloped, positive-strand RNA viruses
belonging to the order Nidovirales. The nonhuman coronavirus
murine hepatitis virus (MHV) is the best-studied coronavirus
and, more importantly, convenient reverse genetics systems are
available to modify its genome (19, 50). MHV has several
appealing characteristics that might make it suitable as an
oncolytic virus. First, it has a narrow host range, determined by
the interaction of its spike (S) glycoprotein with the cellular
receptor mCEACAM1a. Since mCEACAM1a is not expressed
on human cells, MHV cannot establish an infection in either
normal or cancerous human cells. Second, infection by MHV
induces the formation of large multinucleated syncytia, to
which also surrounding uninfected cells are recruited (42).
Hence, given also its relatively short replication cycle (6 to 9 h),
MHV destroys populations of cells rapidly once they have
become infected. Third, the tropism of MHV can be modified
either by substitution of the viral spike ectodomain (19) or by
the use of adapter proteins (43, 47, 48). These adapter pro-
teins, composed of a virus-binding moiety coupled to a target
cell-binding device, can redirect the virus to a specific receptor
on the target cell (43, 47, 48). The studies revealed that, once
the host cell tropism barrier is alleviated, MHV is capable of
establishing infection in nonmurine cells.
The use of adapter proteins to target therapeutic viruses to
tumor cells (modeled in Fig. 1A) is limited by the necessity to
externally provide and replenish the adapter protein. To over-
come this obstacle, the genetic information for the targeting
device can be introduced into the viral genome to allow the
virus to produce the adaptor itself in infected cells, thereby
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creating a self-targeted virus. Indeed, we demonstrated the
feasibility of this concept by expressing an adapter protein—
composed of the relevant (soluble) domain of the
mCEACAM1a receptor linked to a His tag—as an additional
protein from the MHV genome (43). We extend these inves-
tigations here by coupling the epidermal growth factor (EGF)
protein to the mCEACAM1a fragment. Introduction of this
expression cassette encoding the adapter protein allowed mul-
tiround infection in EGF receptor (EGFR)-expressing human
cells, resulting in extensive cell-cell fusion and efficient killing
of target human glioblastoma cells. Using an orthotopic intra-
cranial tumor model of aggressive U87EGFR glioblastomas
in nude mice, we show for the first time that redirected coro-
navirus has oncolytic potential.
MATERIALS AND METHODS
Cells and viruses. Murine LR7 cells (19); feline FCWF-4 cells (34); murine
Ost-7 cells (13), hamster CHO, CHO-His.scFv (18), and CHO-EGFR cells (the
latter two kindly provided by T. Nakamura, Rochester, MN [29]); and human
glioblastoma U373MG, U251MG, Gli6MG, U87MG, and U87EGFR cells (the
generation of U87EGFR is described in reference 31) were all maintained in
Dulbecco modified Eagle medium (Cambrex BioScience, Verviers, Belgium)
containing 10% fetal calf serum, 100 IU of penicillin/ml, and 100 g of strepto-
mycin/ml (all from Life Technologies, Ltd., Paisley, United Kingdom).
Stocks of MHV-EFLM (8), MHVd2aHE (7), recombinant felinized fMHV
(19), and MHVsoR-h-His (43) were grown and titrated as described previously
(43).
Construction of the genes encoding the adapter proteins soR-h-His and soR-
EGF and production of the adapter proteins. The construction of soR-h-His has
been described elsewhere (43). The gene encoding the amino-terminal D1 do-
main of the mCEACAM1a receptor (soR) fused to EGF was generated similarly.
Briefly, to generate the EGF gene, two annealing primers were used as a tem-
plate in a PCR (CATTGCGGCCGCCAATAGTGACTCTGAATGTCCCCTG
TCCCACGATGGGTACTGCCTCCATGATGGTGTGTGCATGTATATTG
AAGCTCTAGACAAGTAT, sense, nucleotides [nt] 1 to 90; and ACTTGGGC
CCGCGCAGTTCCCACCACTTCAGGTCTCGGTACTGACATCGCTCCCC
GATGTAGCCAACAACACAGTTGCATGCATACTTGTCTAGAGCTTC,
antisense, nt 70 to 160) using a forward primer (TGCAGCGGCCGCCAATAG
TGACTCTGAATGT, sense, nt 1 to 18) and a reverse primer (CTAGGCGGC
CGCGCGCAGTTCCCACCACTT, antisense, nt 141 to 159). The resulting
DNA fragment contained a 5 and 3 NotI site (underlined in the primers) and
was subsequently cloned using this restriction enzyme into pSTsoR-His (43), a
derivative of the expression vector pSecTag2 (Invitrogen, Breda, The Nether-
lands), resulting in pSTsoR-EGF. The sequence of the gene encoding the
adapter protein was confirmed by sequencing. Recombinant vaccinia virus
vTF7-3 expressing the bacteriophage T7 RNA polymerase gene was used as a T7
RNA polymerase source for T7 promoter-driven production of the soR adapter
proteins in OST7-1 cells (10) as described previously (43).
Luciferase expression assay. Monolayers of 0.32 cm2 of CHO, CHO-His.scFv,
and CHO-EGFR cells were inoculated with 104 tissue culture infective doses
(TCID50; as determined by endpoint dilution on LR7 cells) of the firefly lucif-
erase-expressing MHV-EFLM (8) preincubated at 4°C for 1 h with the indicated
amounts of adapter proteins. At the indicated time points, the cells were lysed,
and intracellular luciferase expression was measured as described previously
(43).
Targeted RNA recombination. The construction of MHVsoR-h-His by tar-
geted RNA recombination has been described before (43). MHVsoR-EGF was
generated in a similar way; first, a transcription regulation sequence (TRS) was
introduced into pSTsoR-EGF directly upstream of the soR-encoding region to
allow expression of the adapter proteins from an additional expression cassette
in the MHV-A59 genome. Next, the fragment TRS-soR-EGF was cloned in two
successive steps into pMH54 (19), resulting in transcription vector pMHsoR-
EGF suitable for targeted recombination. Targeted RNA recombination was
performed as described previously (7, 19). Briefly, donor RNA transcribed in
vitro from the PacI-linearized plasmid pMHsoR-EGF was transfected by elec-
troporation into feline FCWF-4 cells that had been inoculated at a multiplicity of
infection (MOI) of 0.5 with fMHV 4 h earlier. These cells were then plated in
culture flasks, and the culture supernatant was harvested 24 h later. Progeny virus
was plaque purified, and virus stocks were grown in LR7 cells. After confirmation
of the presence of the additional expression cassette by reverse transcription-
PCR on purified viral RNA from these virus stocks, the titers of the stocks were
determined by endpoint dilution on LR7 cells. These passage 2 virus stocks were
subsequently used in the experiments.
Analysis of viral growth kinetics. An amount of 105 cells per 2-cm2 well of the
indicated cells was inoculated with 0.5  105 TCID50. After 1 h, the culture
supernatant was removed, the cells were washed, and fresh culture medium was
added. At several time points postinfection (p.i.), an 20-l aliquot of the medium
was harvested and stored at 80°C until analysis. The amount of virus produced
at each time point was determined by endpoint dilution on LR7 cells, and the
TCID50 values were calculated.
FIG. 1. Redirection of MHV to the EGFR. (A) Rationale for using
adapter proteins to target viruses to a specific receptor present on
target cells. Adapters, either added or expressed from the viral genome
when incorporated, enable targeted infection of otherwise nonsuscep-
tible cells. (B) Schematic diagram of the expression constructs pSTsoR-
h-His and pSTsoR-EGF. The Ig signal sequence directs adapter pro-
tein secretion, the N-terminal D1 domain of mCEACAM1a (soR)
provides for binding to and induction of conformational changes in the
MHV spike protein, and the six-amino-acid His tag (His) provides for
binding to the artificial His receptor. The hinge (h) linker region
present in soR-h-His allows formation of disulfide-linked dimers of the
resulting adapter protein (43) (T7, T7 promoter; myc, myc tag; ala3,
alanine tripeptide). (C) Targeting of MHV-EFLM to the His receptor
and to the EGFR on CHO cells using soR-h-His and soR-EGF, re-
spectively. CHO, CHO-His.scFv, and CHO-EGFR cells were inocu-
lated with MHV-EFLM preincubated with soR-h-His or soR-EGF,
and the luciferase activities (expressed as relative light units [RLU])
were measured. The values depicted are the means of an experiment
performed in triplicate. Error indicators show the standard deviations.
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Antibody blocking experiments. To determine whether MHVsoR-EGF infec-
tion of CHO-EGFR cells is specifically mediated by the EGFR, cells were
preincubated with different amounts of hybridoma supernatant containing
monoclonal antibody (MAb) 425 directed against the EGFR for 30 min at 4°C.
Next, the cells were inoculated with 104 TCID50 of MHVsoR-EGF for 1 h at
37°C. The cells were washed and incubated for 20 h, after which they were fixed
and stained to analyze the expression of viral proteins.
Immunoperoxidase staining of cell cultures. Cells inoculated with MHVsoR-
h-His or MHVsoR-EGF were fixed with phosphate-buffered saline (PBS) con-
taining 3.7% paraformaldehyde. Immunostainings were performed as described
before (43) using K135 anti-MHV serum (36).
Monolayer cytotoxicity analysis. A total of 5  104 U87EGFR cells per
0.32-cm2 well was seeded and infected the next day in triplicate with MHVsoR-
EGF at an MOI of 5. At several time points after inoculation, the culture
medium was replaced by Dulbecco modified Eagle medium containing 10%
WST-1 (Roche Diagnostics GmbH, Mannheim, Germany), and the cells were
cultured for 30 min. Hereafter, the optical density at 450 nm was measured, and
the viability of the infected cells was determined as described previously (43).
Animal experiments. For assessing the therapeutic effect of MHVsoR-EGF in
vivo, an intracranial glioblastoma xenograft mouse model was applied as de-
scribed previously (20). Eight-week-old female SPF athymic nu/nu mice (Harlan,
Horst, The Netherlands) were stereotactically injected with 105 U87EGFR
cells in 3 l of PBS into the right frontal lobe, 2.5 mm lateral to the bregma at
a depth of 2.5 mm. Injections were done under anesthesia induced by intraperi-
toneal injection of 2 mg of ketamine and 0.4 mg of xylazine in 0.9% saline. After
4 days, 105 MHVsoR-EGF, 105 MHVsoR-h-His, or PBS, all in a total volume of
3 l, was inoculated stereotactically into the same coordinates. Animals were
monitored daily and sacrificed upon manifestation of clinical symptoms, such as
paralysis and lethargy, indicative of a moribund state. From each experimental
group, one animal was sacrificed at day 9 after tumor cell inoculation, while the
others were monitored long term to be able to score for survival (MHVsoR-h-
His and PBS treated [each group composed of eight mice] and MHVsoR-EGF
treated [seven mice; one animal in this group died preliminarily due to an
unrelated cause]). Brains were removed and preserved in 4% neutral-buffered
formaldehyde for histological analyses. Animal experiments were approved by
the local committee on animal experiments and carried out in compliance with
Dutch laws.
Histopathology and immunohistochemistry. The brains were fixed in 4% neu-
tral-buffered formaldehyde overnight and subsequently trimmed and paraffin
embedded. Brain samples that included the area of inoculation were cut into
4-m sections by using a standard microtome (sectioned from cranial to caudal).
Hematoxylin-eosin staining was performed on tissue sections to analyze mor-
phology and the presence of neoplastic cells by light microscopy. Staining for
viral proteins (on seven of seven brains from the MHVsoR-EGF-treated group
and on three of eight brains from the MHVsoR-h-His-treated group) was per-
formed as described by de Haan et al. (6).
Statistical analysis. For mice with intracerebral tumors, statistically significant
differences in survival between treatment group and control groups were as-
sessed by the Wilcoxon test.
RESULTS
Generation of EGFR-directed adapter proteins and their
ability to redirect MHV to the EGFR. The EGFR is currently
considered a very suitable target for virotherapy due to its high
abundance on most tumors. Thus, we designed an adapter
protein composed of the 53-amino-acid EGF protein linked
directly to the N-terminal D1 domain of the MHV receptor
mCEACAM1a (soR) to which we added a C-terminal myc and
His tag. A schematic picture of the construct is depicted in Fig.
1B, along with the control construct lacking the EGF gene
which was optimized for targeting to an artificial His receptor
(43).
Both adapter proteins were produced by using a vaccinia
virus T7 expression system in Ost-7 cells. Western blot analysis
of the culture supernatants using antibodies raised against
N-CEACAM-Fc (15) showed that the adapter proteins were
properly synthesized and secreted (data not shown).
To study the targeting capacities of the soR-EGF adapter
protein, we selected three CHO cell lines: wild-type cells,
which are refractory to MHV infection and without detectable
EGFR expression; CHO-His.scFv cells constitutively express-
ing an artificial His receptor (i.e., a membrane-anchored, sin-
gle-chain antibody that recognizes a six-histidine peptide [18])
and CHO-EGFR cells expressing the wild-type EGFR (29).
MHV-EFLM, an MHV (strain A59) derivative expressing fire-
fly luciferase (8), was incubated with equal amounts of the
adapter proteins (as determined by Western bloting) and sub-
sequently inoculated onto the wild-type or mutant CHO cells.
Luciferase activity was measured to determine whether inoc-
ulation had resulted in successful infection of the target cells
(Fig. 1C). The data show that whereas both soR-EGF and
soR-h-His were able to redirect MHV-EFLM to the CHO-
His.scFv cells, infection of CHO-EGFR cells could only be
achieved by preincubating the virus with soR-EGF and not
with the soR-h-His protein. This result demonstrated that the
infection of CHO-EFGR cells was mediated specifically by the
EGF targeting moiety present in the soR-EGF adapter pro-
tein. Similar inoculations of the parental CHO cell line re-
sulted in background levels of luciferase activity only, both with
soR-h-His and with soR-EGF.
Generation and growth characteristics of recombinant
MHVsoR-h-His and MHVsoR-EGF viruses. Our next aim was
to incorporate the adapter genes into the viral genome in order
to generate viruses that produce their own targeting devices,
thereby acquiring the ability to independently multiply in the
appropriate target cells. Thus, recombinant viruses MHVsoR-
h-His (described elsewhere [43]) and MHVsoR-EGF, both
derivatives of MHV strain A59, in which the adapter genes
replace the viral genes 2a/HE, were produced by using targeted
RNA recombination technology (Fig. 2A). These viruses rep-
licated in murine LR7 cells with similar kinetics and to approx-
imately similar titers as MHVd2aHE, a virus lacking the 2a/HE
genes (Fig. 2B). They were found to stably maintain their
inserts for at least five passages (data not shown).
MHVsoR-EGF can specifically infect EGFR-expressing
cells. To demonstrate that the adapter protein soR-EGF was
produced from the expression cassette in the recombinant
MHVsoR-EGF viruses, CHO-EGFR cells were inoculated
with the recombinant MHV viruses, incubated for 20 h, and
processed for an immunoperoxidase labeling using anti-MHV
serum. Microscopic analysis of the cells showed staining of
viral proteins in cultures inoculated with MHVsoR-EGF but
not in those inoculated with MHVsoR-h-His (Fig. 3A). Large
areas of cell-cell fusion were observed in the MHVsoR-EGF-
infected CHO-EGFR cells, a finding indicative of an intact
fusion capacity of the virus when expressing a soR-EGF
adapter (Fig. 3A; shown at 20 magnification). Inoculation of
wild-type CHO cells did not result in the expression of viral
proteins, indicating that EGFR-negative cells could not be
infected with this virus. The specificity of the targeted infection
was confirmed by showing that the virus could be blocked in a
dose-dependent manner by an MAb directed against the
EGFR (Fig. 3B). The infection could not be fully blocked by
this MAb, which was likely due to the rather low concentration
of this MAb in the culture supernatant of the hybridoma cell
line from which it was obtained.
Analysis of the characteristics of MHVsoR-EGF recombi-
nant virus in human glioblastoma cells. To determine whether
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the soR-EGF-expressing recombinant MHV is able to infect
human tumor cells displaying the EGFR, we selected several
human glioblastoma cell lines, each one expressing the EGFR
endogenously (28), and the U87EGFR cell line additionally
expressing a mutant EGFR gene with a deletion of exon 2-7,
which is a common deletion in glioblastoma tumors (31). The
U373MG, U251MG, Gli6MG, U87MG, and U87EGFR cells
were each inoculated in parallel with MHVsoR-h-His and with
MHVsoR-EGF, fixed at 18 h postinoculation, and processed
for an immunoperoxidase labeling using anti-MHV serum. Mi-
croscopic analysis of the cells showed staining of viral proteins
in all tumor cell cultures inoculated with MHVsoR-EGF but
not in cells inoculated with MHVsoR-h-His virus (Fig. 4A). No
striking differences in the number of infected cells were ob-
served between the different cell lines except for the U251MG
cell line, which displayed somewhat less infection. This re-
duced level of infection did not correspond to a relatively lower
level of the EGFR in these cells (data not shown). Further-
more, all glioblastoma cell lines showed syncytium formation,
a finding indicative of the retained fusion capacity of the MHV
spike protein.
To analyze whether MHVsoR-EGF could establish a mul-
tiround infection of the target cells, we inoculated 5  104
glioblastoma cells with 105 TCID50 units of MHVsoR-EGF (as
titrated on LR7 cells; the infectivity of MHV for glioblastoma
cells was 100- to 1,000-fold lower than for LR7 cells as ob-
served by comparative immunostaining on all cell lines [data
not shown]). Cell viability was measured by WST-1 assay at
different time points after inoculation (Fig. 4B). Our results
showed that MHVsoR-EGF spreads through the U87EGFR
cell cultures, killing increasing numbers of cells and eventually
eradicating the entire culture. Surprisingly, the EGFR-redi-
rected MHV did not affect the viability of the U373MG,
U251MG, Gli6MG, and U87MG cell lines, suggesting that
other intrinsic factors in the tumor cells play a role in the
ability of this virus to kill these cell cultures. As expected,
MHVsoR-h-His did not affect the viability of U87EGFR cell
cultures.
To confirm that the observed killing of U87EGFR cells by
MHVsoR-EGF was due to the production and spread of prog-
eny virus, we prepared an in vitro growth curve of the virus in
these cells, as described in Materials and Methods. Figure 4C
demonstrates that recombinant MHVsoR-EGF virus repli-
cated with normal kinetics and with quite normal yields, reach-
ing maximal titers of 106 to 107 TCID50/ml, as determined by
endpoint dilution on LR7 cells. In contrast, inoculation of
U87EGFR cells with the control virus MHVsoR-h-His did
not, as expected, give rise to progeny virus production.
FIG. 2. Recombinant MHVsoR-h-His and MHVsoR-EGF viruses and their growth kinetics in murine cells. (A) Targeted recombination:
principle, vectors, and recombinant viruses. At the top, the principle of the method is depicted showing the recombination between the recipient
fMHV and the donor in vitro RNA transcript. The transcription vectors from which the RNAs are transcribed in vitro by T7 RNA replicase are
depicted in the middle. The inserted additional expression cassettes encoding soR-h-His and soR-EGF are represented by a grey box. The
recombinant virus genomes generated by targeted RNA recombination are depicted below. (B) Growth kinetics of the MHV recombinants in LR7
cells. LR7 cells were infected at an MOI of 0.5, the production of progeny virus in the culture supernatant at different times p.i. was determined
by endpoint dilution on LR7 cells, and the TCID50 values were calculated. Panels A and B indicate independently generated recombinants.
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In conclusion, the EGFR retargeted MHVsoR-EGF, but
not the control virus MHVsoR-h-His, is able to establish in-
fection and produce progeny virus, with subsequent killing of
the human glioblastoma U87EGFR cells in vitro.
In vivo efficacy studies. U87EGFR cells are known to have
a high tumorigenic capacity in vivo (31). Thus, we decided to
evaluate the oncolytic capacity of the redirected virus in an
established intracranial U87EGFR glioblastoma model in
vivo. In this model, tumor growth is aggressive, often leading to
the appearance of neurological symptoms (such as hemiparesis
and behavioral changes) and ultimately to a moribund decline
and death of mice 21 days after tumor cell injection. Tumors
were established by injection of 105 U87EGFR cells in the
right hemisphere of the mouse brains as described previously
(20). Four days later, mice were injected intracranially at the
same coordinates with either 105 TCID50 MHVsoR-EGF, 10
5
TCID50 MHVsoR-h-His, or PBS. From each group one animal
was sacrificed at day 9 after tumor cell injection (i.e., day 5
after treatment) to analyze initial tumor development in the
acute phase of the infection. The remaining animals in each
group were monitored daily and sacrificed when obvious neu-
rological symptoms appeared or when a weight loss exceeding
20% of the original weight was observed.
Treatment with MHVsoR-EGF had a dramatic effect on
survival (Fig. 5). Survival times of the animals were signifi-
cantly extended compared to both MHVsoR-h-His- and PBS-
treated mice (P 	 0.004 and P 	 0.001, respectively). No
significant difference between survival of PBS- and control
virus-treated mice was observed (P 	 0.33). The observed
median survival times were 16, 19.5, and 41 days for PBS-,
control virus-, and redirected virus-treated mice, respectively.
Histopathological analysis of hematoxylin-eosin-stained sec-
tions of the brains removed from animals killed at day 9 after
glioblastoma cell injection revealed the presence of neoplasms
in the brains of the PBS- and MHVsoR-h-His treated mice,
whereas in the brain of the MHVsoR-EGF treated mouse no
neoplasm could be observed (shown in Fig. 6A, Day 9). Serial
sections of all brains showed significant cyst formation in the
area of injection. These cysts were optically largely empty,
showing some extravasated erythrocytes and various numbers
of macrophages with lipofuscin, hemosiderin pigment, and
neutrophils. It is of note that no clinical symptoms were ob-
served in any of the mice at this time point in the study (Day 9).
At the onset of significant neurological symptoms (e.g., pa-
ralysis) and/or weight loss, animals were sacrificed. His-
topathological analysis of the brains of sacrificed mice (indi-
cated, Day 
 9 in Fig. 6A revealed large neoplasms in all
brains inoculated with PBS and in six of seven analyzed brains
of mice treated with the control virus. In contrast, no tumor
load could be detected in the brains of six of seven mice treated
FIG. 3. Receptor specificity of MHVsoR-EGF recombinant virus. (A) Immunoperoxidase staining of CHO-EGFR and CHO-wt cells inocu-
lated with MHVsoR-h-His and MHVsoR-EGF recombinant viruses using anti-MHV serum K135. Images are shown at 4 magnification, and
images for the recombinant MHVsoR-EGF virus syncytium formation are also shown at 20 magnification. (B) MHVsoR-EGF was inoculated
onto CHO-EGFR cells preincubated for 1 h at 4°C in the absence or presence of increasing amounts of anti-EGFR MAb 425. At 20 h p.i., the
cells were fixed, permeabilized, and stained for MHV protein expression using anti-MHV serum K135. The number of stained cells was counted
and is depicted relative to the number of positive cells counted in the control culture preincubated in the absence of MAb 425. The data represent
the relative number of infected cells compared to mock-treated cells. Error bars show the standard deviations of experiments performed in
triplicate.
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with the retargeted MHVsoR-EGF (a representative example
is shown in Fig. 6A, Day 
 9). The animal treated with the
control virus in which no neoplasm could be detected survived
the longest in this group (34 days).
Immunohistochemical staining of sections with virus-specific
polyclonal antiserum, counterstained with hematoxylin-eosin,
showed viral protein expression in nonneoplastic tissue of the
brains of MHVsoR-EGF- and MHVsoR-h-His-injected mice
at day 9. At the time of sacrifice due to severe symptoms, five
of seven analyzed MHVsoR-EGF-treated brains showed
MHV-specific staining in nonneoplastic tissue (an example of
an MHVsoR-EGF-treated brain obtained at day 43 is shown in
Fig. 6B). Relative levels of infection of neoplastic and nonneo-
plastic tissue could not be determined in these brains, since no
neoplastic tissue was present in any of these cases. One of the
brains that could not be stained with MHV antibodies was of
the single animal in which a tumor was observed at t 
 9 days
after injection with MHV-soR-EGF. In two of three analyzed
control virus-treated mice, staining was observed, whereas no
staining was observed in PBS-inoculated brains.
Despite the lack of neoplasms in six of seven mice treated
with MHVsoR-EGF, these mice suffered from neurological
symptoms, with ultimate moribund decline. Histopathological
analyses of the brains revealed cystic structures with similar
morphology as noted in animals killed after 9 days in five of six
neoplasm-free animals treated with MHVsoR-EGF and also in
the one mouse treated with MHVsoR-h-His without a neo-
plasm that was killed at a later stage of the experiment.
DISCUSSION
Despite great efforts, the treatment options for patients with
malignant brain tumors are still very limited. Due to their often
widely ramified nature and their anatomical location, complete
surgical resection of these tumors is often not feasible. Hence,
creative, minimally invasive new strategies are required among
which virotherapy seems, at least conceptually, the most
straightforward approach. We continued here our explorations
of the potential of a new candidate oncolytic virus in vivo. We
demonstrate that the nonhuman coronavirus MHV can be
redirected to the EGFR by using adapter proteins consisting of
a soluble mCEACAM1a receptor arm fused to the EGF pro-
tein. Genetic incorporation of the adapter sequence in the viral
genome was tolerated, and the virus retained its ability to
induce cell-cell fusion and produce progeny virus. Moreover,
this recombinant virus mediated efficient cell killing of the
human glioblastoma cell line U87EGFR. Most importantly,
the redirected virus MHVsoR-EGF was effective in eradicat-
ing the highly aggressive U87EGFR tumor in an orthotopic
mouse model. To our knowledge, this is the first evidence
demonstrating in an animal model that coronaviruses have
potential as antitumor agents.
Recently, we showed that the species barrier of coronavi-
ruses can be alleviated by using adapter proteins (43, 47, 48).
These adapter proteins were constructed in such a way that
either both arms encoded single chain antibody fragments
(scFv; e.g., the bispecific scFvs directed against the feline spike
protein and the EGFR [48]), both arms encoded “regular”
genes (e.g., the soluble mCEACAM1a and the artificial His tag
[43]), or a combination of the two (e.g., soluble mCEACAM1a
fused to the scFv directed against EGFR [47]). It appeared
that the incorporation of adapter proteins consisting of either
one or two scFvs in the viral genome was not tolerated by
MHV; viruses expressing the adapter gene could not be stably
maintained (unpublished data). Fortunately, such viruses
could be prepared and maintained when the adapter gene was
composed of sequences encoding the soluble mCEACAM1a
receptor linked to an artificial His tag (43) or to EGF (the
manuscript). The recombinant MHVs grew with characteristics
comparable to those of MHVd2aHE, a similar virus lacking
the adapter genes. Most likely, it is the sequence composition
of the scFvs rather than insert size constraints that resist stable
maintenance in the viral genome, since the introduction of
significantly larger sequences has been successfully achieved
earlier (8).
The in vivo oncolytic activity of our redirected MHV against
the highly aggressive brain tumor U87EGFR (31) appeared
to be fast and lasting. Soon after virus inoculation, most of the
tumor was found to be destroyed, and no recurrent tumor was
FIG. 4. Infection, cell killing, and progeny virus production in MHVsoR-EGF inoculated human glioblastoma cell lines. (A) Immunoperoxi-
dase staining of EGFR-expressing human glioblastoma U373MG, U251MG, Gi6MG, U87MG, and U87EGFR cells inoculated with recombinant
virus MHVsoR-h-His or MHVsoR-EGF using anti-MHV serum K135. (B) Cell viability of glioblastoma U373MG, U251MG, Gi6MG, U87MG,
and U87EGFR cell lines after inoculation with MHVsoR-h-His and MHVsoR-EGF. The cell viability was measured at different time points after
inoculation and is depicted relative to uninfected control cells. (C) Growth kinetics of MHVsoR-h-His and MHVsoR-EGF in U87EGFR cells.
The production of progeny virus in the culture media at different times postinfection was determined by endpoint dilution on murine LR7 cells,
and the TCID50 values were calculated.
FIG. 5. In vivo oncolytic activity of MHVsoR-EGF. Mice with es-
tablished intracranial U87EGFR tumors were treated with MHVsoR-
EGF, MHVsoR-h-His or PBS at 4 days after tumor cell inoculation.
The animals were monitored, and mice with obvious neurological
symptoms or weight loss exceeding 20% of the original weight were
euthanized. The Kaplan-Meier curves showing survival of mice are
depicted.
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observed in this orthotopic model in six of seven MHVsoR-
EGF-treated animals. The single animal that had neoplastic
tissue lacked any immunohistochemical staining for MHV,
suggesting that the redirected virus had not been applied cor-
rectly. One other striking outlier was the animal in the control
virus-treated group that survived the longest and in which no
tumor tissue was observed, implying that this single
U87EGFR implantation had not been successful, since all
other animals in this group developed large neoplasms.
One obvious drawback to studying the oncolytic capacity of
MHV in a mouse model is the virus’ natural tropism. It has
been shown that MHV strain A59, the genetic background of
our control and retargeted viruses, is weakly neurovirulent and
causes demyelination in immunocompetent mice (38). How-
ever, no demyelination was observed in the brains of mice
treated with the retargeted virus, since immunohistochemical
staining with an antibody to the myelin basic protein appeared
similar in infected and PBS control mouse brains (data not
shown). Our recombinant MHV-A59 viruses lack the virulence
gene cluster 2a/HE, a deletion that appeared to attenuate the
virus as judged after intracranial inoculation in C57BI/6 mice (7).
However, mouse tissue is likely to be still permissive to the
recombinant viruses since they can be propagated in murine
LR7 cells in vitro. Furthermore, our histopathological studies
revealed cyst formation and secondary inflammatory changes.
Moreover, we did observe substantial loss of tissue within the
FIG. 6. Histopathological analysis of brains. (A) Representative hematoxylin-eosin stained slides of brains excised at 9 days (Day 9) or at a later
day of euthanasia due to the occurrence of neurological symptoms (Day 
 9) after establishing the U87EGFR xenografts (for PBS-, control-,
and targeted virus-treated mice days 17, 16, and 43 days after tumor cell injection, respectively). Large neoplasms and cystic structures are indicated
by “N” and “C,” respectively. (B) Immunohistochemical staining for viral proteins using polyclonal MHV antibody K135 and counterstained with
hematoxylin. Shown is a section of the brain of an MHVsoR-EGF-treated U87EGFR xenograft at the time of sacrifice (43 days after tumor cell
injection). Note the appearance of immunoreactivity mainly in astrocytes and the absence of marked pathology.
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injected area resulting in the formation of cysts with secondary
local granulomatous and neutrophilic inflammation in both
acute and later stages. The cysts most likely resulted from
liquefactive necrosis of neoplastic tissue and not of necrosis of
preexistent neural tissue. This is suggested by the absence of
morphological indications of degeneration, necrosis, or inflam-
mation in preexisting areas in the brain where MHV antigen
was detected immunohistochemically. Liquefactive necrosis
within the central nervous system typically results in cystic
structures since the formation of granulation tissue, as is ob-
served in other tissues during damage repair, does not occur in
the central nervous system. In conclusion, the neurological
symptoms recorded in the animals are probably related to
growth of the neoplasms and/or formation of cystic structures
in the brain tissue. Most likely, replication of the targeted
MHV in nonneoplastic brain tissue caused the neurological
symptoms observed in the mice treated with MHVsoR-EGF.
Several other viruses have been explored for their potential
as oncolytic agents against glioblastomas. The first one genet-
ically engineered and proven to be efficient in an experimental
glioblastoma model was herpes simplex virus (27). Among the
ones that followed were lentiviruses (40), vesicular stomatitis
virus (24, 33), myxoma virus (25), measles virus (1), Newcastle
disease virus (5, 12), and adenoviruses (reviewed in references
17 and 39). One major advantage of nonhuman coronaviruses
is that they have a very short replication cycle, resulting in fast
clearance of the tumor cells (already observed at day 5 post-
inoculation, Fig. 6). Their ability to cause cell-cell fusion of
infected with noninfected neighboring cells is likely to contrib-
ute to this. Furthermore, MHV does not infect humans, so its
natural tropism does not need to be ablated, nor will preexist-
ing antibodies dampen its reproduction. The EGFR is an in-
triguing target in high-grade glioblastomas because it is often
abundantly overexpressed (9, 21, 46). Moreover, the most fre-
quently identified mutant EGFR in malignant glioblastomas is
EGFRvIII, as is the case in U87EGFR cells (11, 41, 49).
EGFR is, however, also present to some extent on nonneo-
plastic tissue in the brain, indicating that improving the selec-
tivity of targeting might be required.
Intriguingly, overcoming the entry barrier was not the only
requirement for establishing a productive MHV infection. Al-
though postentry blocks of viral replication have been de-
scribed for several viruses (reviewed in reference 2), this has
never been observed for MHV. Rather, the presence of the
viral receptor mCEACAM1a thus far appeared to be the sole
requirement for MHV multiplication. As we found out when
inoculating several EGFR-expressing human glioblastoma
cells with our self-targeted MHVsoR-EGF, successful infec-
tion including the induction of syncytium formation was
achieved in all cases. Surprisingly, however, the infection did
not spread and eradicate the culture except in one case, the
U87EGFR cells, which were efficiently killed by the virus.
Although not studied here, it is unlikely that binding to the
mutant EGFR (EGFR or EGFRvIII) additionally expressed
in the U87EGFR cell line accounts for this difference since
EGFRvIII is unable to bind EGF as a ligand (31), and EGFR
levels are comparable for U87MG and U87EGFR (31).
Thus, although alleviation of the tropism barrier seems to be a
prerequisite for MHV infection, its oncolytic properties might
depend on other cellular signaling events, such as interferon
signaling (as observed for poxvirus, vesicular stomatitis virus,
and Newcastle disease virus), p53 (30), or Ras (4, 32). For
instance, Ras activation mediates reovirus oncolysis by enhanc-
ing virus uncoating, particle infectivity, and apoptosis-depen-
dent release (26). Moreover, it has been shown that EGFR
overexpression or its aberrant functioning can lead to Ras
activation (23). Hence, since U87EGFR is constitutively ac-
tive in EGFR signaling due to its deletion of exon 2-7, it will be
of interest to investigate whether coronavirus replication is
also affected by the Ras pathway.
The significant oncolytic activity of the new, redirected ani-
mal coronavirus observed in the present study seems to war-
rant further studies. In view of the complications associated
with using a murine virus in a murine model, shifting to a
relevant nonmouse model, such as immune deficient rats,
seems the most logical option, since MHV does not replicate in
other mammalian species. Such studies will hopefully allow us
to establish oncolytic efficacy of the recombinant MHV in
immunocompetent animals, as well as in other tumors.
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